JHL delisting from TPEx

JHL Biotech Inc. (TPEx-E:6540) said it will voluntarily delist from the Taipei Exchange in a move that its board believes will allow the company to advance and expand its biosimilars pipeline. The company said it will explore fund-raising strategies, including a potential listing on another exchange.

JHL was viewed as a potential bellwether for Taiwan biotech. Before going public, JHL raised $121.6 million in a trio of venture rounds -- the largest sum among Taiwanese companies, according to BioCentury's BCIQ database at the time of the IPO. JHL listed on the Taiwan's Emerging Stock Board of TPEx in September 2015 at a NT$1.9 billion ($57.5 million) valuation...